Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study. [PDF]
Diabetes Metab Syndr ObesItsukaichi A +7 more
europepmc +1 more source
DPP-4 Inhibitor-associated Bullous Pemphigoid in a Hemodialysis Patient. [PDF]
Intern Med, 2020 Usami J, Takezawa Y.
europepmc +1 more source
DPP-4 inhibitor sitagliptin treatment results in altered myocardial metabolic proteome and oxidative phosphorylation in a swine model of chronic myocardial ischemia. [PDF]
Physiol RepHarris DD +7 more
europepmc +1 more source
Possibility of pharmacokinetic drug interaction between a DPP-4 inhibitor and a SGLT2 inhibitor. [PDF]
Transl Clin Pharmacol, 2020 Gu N +5 more
europepmc +1 more source
Effect of DPP-4 inhibitor on elderly patients with T2DM combined with MCI. [PDF]
Exp Ther Med, 2020 Xue J +7 more
europepmc +1 more source
Glycemic control of once-weekly and other administration frequencies for DPP-4 inhibitor in patients with type 2 diabetes: a real-world retrospective cohort study. [PDF]
Diabetol IntKoto R +4 more
europepmc +1 more source
PRE1BRAZIL Protocol: A Randomized Controlled Trial to Evaluate the Effectiveness and Safety of the DPP-4 Inhibitor Alogliptin in Delaying the Progression of Stage 2 Type 1 Diabetes. [PDF]
Diabetes Metab Syndr ObesPenaforte-Saboia JG +10 more
europepmc +1 more source
Improvement of Glycemia by DPP-4 Inhibitors
Journal of the Japan Diabetes Society, 2013 Nishi, Y., Fujimoto, S.
openaire +1 more source
The DPP-4 inhibitor sitagliptin improves glycaemic control and early-stage diabetic nephropathy in adolescents with type 1 diabetes using the MiniMed 780G advanced hybrid closed-loop system: a randomised controlled trial. [PDF]
DiabetologiaElbarbary NS +4 more
europepmc +1 more source